Company: SXTPW
Filing Date: 2025-07-07
Form Type: S-1
Source: 0001213900-25-061842
Chunk: 27

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-07-07
Form: S-1
Chunk 27
---
 developed
as drug combinations to proactively combat drug resistance. We believe that Tafenoquine, due to its long half-life and activity against
all parasite species and strains, would be an ideal partner in a drug combination. Recently, Kentucky Technology Inc. (“KTI”),
completed Phase IIA studies in P. vivax malaria, in which they evaluated the safety and efficacy of SJ733, their ATP4 inhibitor
in combination with Tafenoquine as the combination partner drug. It was recently announced that the SJ733 development program would be
partially supported by a grant from the Global Health Innovative Technology Fund (“GHIT”). As part of its shares for services
agreement with KTI, the Company recently received a detailed feasibility assessment and business plan for the project, including an assessment
of potential PRV eligibility. The Company has provided KTI with a right of reference to its Arakoda IND, in order to assist with regulatory
approvals of forthcoming clinical trials.

Celgosivir for Antiviral Diseases

Reviewing prior studies of Celgosivir for Zika,
Dengue and RSV, it is evident that the drug protects against the pathological effects of viruses through a combination of anti-inflammatory
and antiviral effects. These properties suggest it might have a beneficial effect in several viral diseases. Celgosivir is synthesized
from Castanospermine, which is obtained from botanical sources in low yield. Castanospermine is also quite water soluble, making it amenable
to intravenous formulation. As of the date of this prospectus, The Florida State University Research Foundation, Inc. (“FSURF”)
had sold their remaining shares of common stock of the Company, and funds raised therefrom were insufficient to cover the cost of the
proof of concept studies in a hamster model of COVID-19 that we had originally planned. We instead intend to investigate the potential
activity of celgosivir in other respiratory viruses in different non-clinical models.

Castanospermine/Australian Chestnut Tree Extracts

Extensive scientific literature suggests castanospermine
has broad antiviral, metabolic and immunomodulatory effects by virtue of its inhibition of host glucosidases (enzymes that break down
glucose-containing polymers). These properties suggest it might provide support to patients suffering numerous conditions. Botanical extracts
require only a 75-day notification to the FDA, and do not require clinical trials or pre-marketing approval. The Company currently has
at